|
|||||
|
|
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study |
|
| Authors: | K. Reich P. Rich C. Maari R. Bissonnette C. Leonardi A. Menter A. Igarashi P. Klekotka D. Patel J. Li J. Tuttle M. Morgan-Cox E. Edson-Heredia S. Friedrich K. Papp the AMAF investigators |
| Affiliation: | 1. Dermatologikum Berlin, Berlin, Germany;2. Dermatology and Clinical Research, Oregon Health Science University, Portland, OR, U.S.A.;3. Innovaderm Research, Montreal, QC, Canada;4. St Louis University School of Medicine, St Louis, MO, U.S.A.;5. Department of Dermatology, Baylor University Medical Center, Dallas, TX, U.S.A.;6. NTT Medical Center Tokyo, Tokyo, Japan;7. Eli Lilly and Company, Indianapolis, IN, U.S.A.;8. Probity Medical Research, Waterloo, ON, Canada |
| Abstract: | |
| Keywords: | |